One dose vs two doses of G-CSF for stem cell donors
This trial compares giving a single dose of G-CSF versus splitting it into two doses to see which works better for collecting stem cells from healthy bone marrow donors. The goal is to find a simpler and possibly more comfortable way to help donors produce enough stem cells for transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You are willing to donate stem cells for a family member or matched patient.
- You have a healthy blood count (white blood cells, neutrophils, and platelets above certain levels).
- You weigh at least 40 kg (about 88 lbs) if female, or 45 kg (about 99 lbs) if male.
- You do not have any major medical condition (like heart, liver, kidney disease, cancer, or active infection).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a stem cell-mobilizing medicine (G-CSF) at a specific time of day based on your natural sleep/wake rhythm can improve the collection of blood stem cells from healthy donors. It aims to make the donation process more efficient and comfortable.
This study tests improved ways to select and collect bone marrow cells from healthy donors for use in transplants. Researchers are looking for healthy volunteers to donate cells that may help people who need bone marrow transplants.
This study tests a better way to collect white blood cells from healthy people who donate blood. It may help improve how reliably and safely white blood cells are collected for research or future treatments.
This Phase 3 study tests using filgrastim (a medicine that helps stem cells leave the bone marrow) to collect stem cells from unrelated donors for transplant. It focuses on donor safety and whether this collection method works well enough for transplantation.
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hear when a new Healthy Hematopoietic Stem Cell Donor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.